Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction

https://doi.org/10.20996/1819-6446-2022-04-01

Abstract

Aim. To study the effects of azilsartan medoxomil/chlorthalidone (AZM/CTD) and losartan/hydrochlorothiazide (LOS/HCT) combinations for NTproBNP levels, 6-minute walk test results, hydration status along with their antihypertensive efficacy according to clinical and 24-hour blood pressure in patients with hypertension and heart failure with preserved ejection fraction (HFpEF).

Material and methods. An open randomized study included 56 patients with uncontrolled or untreated hypertension and HFpEF. Patients randomized to receive the AZM/CTD 40/12.5 mg/day (group 1; n=28) or LOS/HCT 100/12.5 (group 2; n=28) within 4 weeks. Patients who did not achieve the target BP <140/<90 mm Hg study drug dose was intensified: in the first group, an increase in the dose of AZM/CTD 40/25 mg/day, in the second group, an increase in the dose of LOS/HCT 100/25 mg/day. The observation period was 12 weeks. All patients underwent a clinical examination with an assessment of symptoms and/or signs of HF, laboratory and instrumental studies, including NT-proBNP, ambulatory blood pressure (BP) monitoring, applanation tonometry, a 6-minute walk test (6MWT), echocardiography. In order to assess the status of hydration, bioimpedance vector analysis (BIVA) was performed. HFpEF was diagnosed according to the HFA-PEFF algorithm. The results were considered statistically significant at p<0.05.

Results. After 12 weeks, 92% of patients in the first and 78% of patients in the second group reached the target clinical BP (р<0,05). Average daily BP <130/ <80 mm Hg was reached by 82% of patients treated with the combination of AZM/CTD, compared with 67% treated with the combination of losartan/HCT (p<0.05). After 12 weeks, patients from both groups showed a significant decrease in systolic and diastolic blood pressure, central blood pressure, and a decrease in pulse wave velocity, which was more significantly significant in the first group of patients (p<0.05). During therapy in both groups of patients, a significant decrease in the level of NT-proBNP was observed: in the first group from 300 [199; 669] pg/ml to 156 [157; 448] pg/ml (p=0,003), in the second group from 298 [180; 590] pg/ml to 194 [140; 360] pg/ml (p=0,006), an increase in the distance during the 6MWT from 317 [210; 398] m to 380 [247; 455] m (p=0,006) in in the first group and an improvement in the hydration status according to the BIA data, but more significantly significant in the first group (p<0.001).

Conclusion. In patients with hypertension and HFpEF, therapy with the AZM/CTD combination compared with LOS/HCT is accompanied by a more pronounced antihypertensive effect in terms of ambulatory and peripheral blood pressure, central blood pressure, NTproBNP levels, increased distance in 6MWT and achievement of euvolemia status. 

About the Authors

Zh. D. Kobalava
Peoples Friendship University of Russia (RUDN)
Russian Federation

Zhanna D. Kobalava

Moscow



A. F. Safarova
Peoples Friendship University of Russia (RUDN)
Russian Federation

Ayten F. Safarova

Moscow



Kh. M. Gudieva
Peoples Friendship University of Russia (RUDN)
Russian Federation

Khyadi M. Gudieva

Moscow



M. A. Markova
Peoples Friendship University of Russia (RUDN)
Russian Federation

Maria A. Markova

Moscow



A. E. Petrosyan
Peoples Friendship University of Russia (RUDN)
Russian Federation

Anush E. Petrosyan

Moscow



References

1. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591-602. DOI:10.1038/nrcardio.2017.65.

2. Slivnick J, Lampert BC. Hypertension and Heart Failure. Heart Fail Clin. 2019;15(4):531-41. DOI:10.1016/j.hfc.2019.06.007.

3. Gladden JD, Chaanine AH, Redfield MM. Heart Failure with Preserved Ejection Fraction. Annu Rev Med. 2018;69:65-79. DOI:10.1146/annurev-med-041316-090654.

4. Tadic M, Cuspidi C, Frydas A, Grassi G. The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more? Heart Fail Rev. 2018;23(5):6319. DOI:10.1007/s10741-018-9698-8.

5. Mareev VYu, Danielyan MO, Belenkov YuN. Comparative characteristics of patients with CHF in relation to the value of injection fraction by data from the Russian multicenter study EPOCH A CHF: once more about the problem of CHF with preserved left ventricular systolic function. Heart Failure Journal. 2006;7(4):164-71 (In Russ.)

6. Pfeffer MA. Heart Failure and Hypertension: Importance of Prevention. Med Clin North Am. 2017;101(1):19-28. DOI:10.1016/j.mcna.2016.08.012.

7. Piepoli MF, Adamo M, Barison A, et al. Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. Eur J Heart Fail. 2022 Jan;24(1):143-68. DOI:10.1002/ejhf.2351.

8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97. DOI:10.1001/jama.288.23.2981.

9. Grimm RH, Davis BR, Piller LB, et al. ALLHAT Collaborative Research Group. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? J Clin Hypertens (Greenwich). 2009;11(9):466-74. DOI:10.1111/j.1751-7176.2009.00149.x.

10. Davis BR, Kostis JB, Simpson LM, et al. ALLHAT Collaborative Research Group. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118(22):2259-67. DOI:10.1161/CIRCULATIONAHA.107.762229.

11. Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective Effect of Thiazide-Like Diuretics: A MetaAnalysis. Am J Hypertens. 2015;28(12):1453-63. DOI:10.1093/ajh/hpv050.

12. Pareek AK, Messerli FH, Chandurkar NB, Dharmadhikari SK, et al. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. J Am Coll Cardiol. 2016;67(4):379-89. DOI:10.1016/j.jacc.2015.10.083.

13. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47(3):352-8. DOI:10.1161/01.HYP.0000203309.07140.d3.

14. Sica D, White WB, Weber MA, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2011;13(7):467-72. DOI:10.1111/j.1751-7176.2011.00482.x.

15. Rakugi H, Enya K, Sugiura K, Ikeda Y. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012; 35(5):552-8. DOI:10.1038/hr.2012.8.

16. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich). 2011;13(2):81-8. DOI:10.1111/j.1751-7176.2010.00425.x.

17. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413-20. DOI:10.1161/HYPERTENSIONAHA.110. 163402.

18. Wang JG, Zhang M, Feng YQ, et al. Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis. J Clin Hypertens (Greenwich). 2021;23(5):901-14. DOI:10.1111/jch.14227.

19. Nedogoda SV, Chumachek EV, Tsoma VV, et al. Effectiveness of in insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs. Russian Journal of Cardiology. 2019;(1):70-9 (In Russ.) DOI:10.15829/1560-4071-2019-1-70-79.

20. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125(12):1229.e1-1229.e10. DOI:10.1016/j.amjmed.2012.05.023.

21. Kobalava ZD, Kulakov VV, Goreva LA, Villevalde SV. Comparative analysis of antihypertensive effects of chlorthalidone and indapamide-retard in combination with azilsartan medoxomil in patients with arterial hypertension. Russian Journal of Cardiology. 2019;(6):122-30 (In Russ.) DOI:10.15829/1560-4071-2019-6-122-130.

22. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-16. DOI:10.1056/NEJMoa1511939.

23. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297317. DOI:10.1093/eurheartj/ehz641.

24. Lancellotti P, Pellikka PA, Budts W, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2016;17(11):1191-1229. DOI:10.1093/ehjci/jew190.

25. Mamatov BM, Villevalde SV, Klimenko AS, Kobalava ZD. Bioimpedance vector analysis for detecting subclinical congestion in patients with decompensated heart failure. Clin Pharmacol Ther. 2016;25(5):45-9 (In Russ.)

26. Park CS, Lee SE, Cho HJ, et al. Body fluid status assessment by bio-impedance analysis in patients presenting to the emergency department with dyspnea. Korean J Intern Med. 2018;33(5):91121. DOI:10.3904/kjim.2016.358.

27. Parrinello G, Paterna S, Di Pasquale P, et al. The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure. J Card Fail. 2008;14(8):676-86. DOI:10.1016/j.cardfail.2008.04.005.

28. Alves FD, Souza GC, Aliti GB, et al. Dynamic changes in bioelectrical impedance vector analysis and phase angle in acute decompensated heart failure. Nutrition. 2015;31(1):84-9. DOI:10.1016/j.nut.2014.05.004.

29. Koell B, Zotter-Tufaro C, Duca F, et al. Fluid status and outcome in patients with heart failure and preserved ejection fraction. Int J Cardiol. 2017;230:476-481. DOI:10.1016/j.ijcard.2016.12.080.

30. Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310-8. DOI:10.1161/HYPERTENSIONAHA.111.188284.

31. Starostina E, Troitskaya E, Kulakov V, et al. Azilsartan medoxomil decreases 24-h central BP and arterial stiffness in patients with arterial hypertension and type 2 diabetes mellitus. J Hypertens. 2017;35 (e-Supplement 2): e106.

32. Skibitskiy VV, Fendrikova AV, Sirotenko DV, et al. Chronotherapeutic aspects of the efficacy of combination treatment with azilsartan medoxomil in patients with arterial hypertension and metabolic syndrome. Kardiologiia. 2016;56(10):35-40 (In Russ.)DOI:10.18565/cardio.2016. 10.35-40.

33. Perepech NB, Chazova IE, Zhernakova JuV. Efficacy and safety of azilsartan medoxomil in various doses in patients with metabolic disorders. Systemic Hypertension. 2021;18(3):130-9 (In Russ.) DOI:10.26442/2075082X.2021.3.201078.

34. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Followup Program Cooperative Group. JAMA. 1979;242(23):2562-71.

35. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82(5):1616-28. DOI:10.1161/01.cir.82.5.1616.

36. Shah SJ, Borlaug BA, Kitzman DW, et al. Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary. Circulation. 2020;141(12):1001-26. DOI:10.1161/CIRCULATIONAHA.119.041886.


Review

For citations:


Kobalava Z.D., Safarova A.F., Gudieva K.M., Markova M.A., Petrosyan A.E. Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction. Rational Pharmacotherapy in Cardiology. 2022;18(2):127-134. (In Russ.) https://doi.org/10.20996/1819-6446-2022-04-01

Views: 385


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)